Novavax, Inc. (NASDAQ:NVAX) Shares Acquired by Parametric Portfolio Associates LLC

Parametric Portfolio Associates LLC boosted its holdings in shares of Novavax, Inc. (NASDAQ:NVAX) by 72.7% in the 2nd quarter, Holdings Channel reports. The firm owned 81,527 shares of the biopharmaceutical company’s stock after buying an additional 34,307 shares during the period. Parametric Portfolio Associates LLC’s holdings in Novavax were worth $17,309,000 at the end of the most recent reporting period.

Other hedge funds have also added to or reduced their stakes in the company. Quadrant Capital Group LLC lifted its position in shares of Novavax by 58.1% in the 2nd quarter. Quadrant Capital Group LLC now owns 166 shares of the biopharmaceutical company’s stock valued at $35,000 after acquiring an additional 61 shares in the last quarter. Valley National Advisers Inc. lifted its position in shares of Novavax by 25.6% in the 2nd quarter. Valley National Advisers Inc. now owns 392 shares of the biopharmaceutical company’s stock valued at $83,000 after acquiring an additional 80 shares in the last quarter. Wedbush Securities Inc. lifted its position in shares of Novavax by 2.8% in the 2nd quarter. Wedbush Securities Inc. now owns 3,724 shares of the biopharmaceutical company’s stock valued at $791,000 after acquiring an additional 100 shares in the last quarter. Firestone Capital Management lifted its position in shares of Novavax by 200.0% in the 2nd quarter. Firestone Capital Management now owns 150 shares of the biopharmaceutical company’s stock valued at $32,000 after acquiring an additional 100 shares in the last quarter. Finally, Quadrant Private Wealth Management LLC lifted its position in shares of Novavax by 5.5% in the 2nd quarter. Quadrant Private Wealth Management LLC now owns 1,908 shares of the biopharmaceutical company’s stock valued at $405,000 after acquiring an additional 100 shares in the last quarter. 52.77% of the stock is owned by institutional investors and hedge funds.

In other news, CEO Stanley C. Erck sold 42,829 shares of the stock in a transaction on Monday, October 4th. The shares were sold at an average price of $176.15, for a total transaction of $7,544,328.35. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider Gregory M. Glenn sold 1,386 shares of the firm’s stock in a transaction on Tuesday, August 31st. The shares were sold at an average price of $239.87, for a total transaction of $332,459.82. Following the completion of the transaction, the insider now owns 5,394 shares in the company, valued at $1,293,858.78. The disclosure for this sale can be found here. In the last quarter, insiders sold 226,332 shares of company stock worth $43,023,648. Company insiders own 2.10% of the company’s stock.

Novavax stock opened at $200.07 on Thursday. The firm has a market cap of $15.13 billion, a PE ratio of -13.51 and a beta of 1.28. The company has a debt-to-equity ratio of 0.70, a quick ratio of 1.43 and a current ratio of 1.24. The firm’s 50 day moving average price is $181.58 and its two-hundred day moving average price is $193.04. Novavax, Inc. has a twelve month low of $94.67 and a twelve month high of $331.68.

Novavax (NASDAQ:NVAX) last released its quarterly earnings data on Thursday, November 4th. The biopharmaceutical company reported ($4.31) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($4.04) by ($0.27). The company had revenue of $178.80 million during the quarter, compared to analyst estimates of $347.34 million. Novavax had a negative net margin of 89.31% and a negative return on equity of 149.66%. The firm’s quarterly revenue was up 13.9% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($3.21) EPS. Equities analysts anticipate that Novavax, Inc. will post -11.84 EPS for the current fiscal year.

Several equities research analysts recently commented on the stock. Chardan Capital restated a “neutral” rating on shares of Novavax in a research report on Wednesday, September 1st. Zacks Investment Research upgraded shares of Novavax from a “sell” rating to a “hold” rating and set a $246.00 price target for the company in a research report on Thursday, August 12th. Three analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Buy” and an average target price of $249.00.

Novavax Company Profile

Novavax, Inc focuses on the discovery, development and commercialization of vaccines to prevent infectious diseases. It provides vaccines for COVID-19, seasonal flu, respiratory syncytial virus, Ebola, and Middle East respiratory syndrome. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Read More: Price to Earnings Ratio (PE)

Want to see what other hedge funds are holding NVAX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novavax, Inc. (NASDAQ:NVAX).

Institutional Ownership by Quarter for Novavax (NASDAQ:NVAX)

Receive News & Ratings for Novavax Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novavax and related companies with MarketBeat.com's FREE daily email newsletter.